A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II)

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Moderate to severe rheumatoid arthritis according to the revised 1987 ACR criteria at baseline * RoActemra/Actemra treatment must have been initiated 6 months prior to ICF signing * Patient eligible according to the summary of product characteristics (SPC) and routine clinical practice/European recommendations for the use of biologic DMARDs for the treatment of rheumatoid arthritis Exclusion Criteria: * Rheumatic autoimmune disease other than RA * Participation in interventional clinical trials during the observational period